

# Yeng S Ang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7418453/publications.pdf>

Version: 2024-02-01

40  
papers

2,393  
citations

471061

17  
h-index

276539

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2788  
citing authors

#	ARTICLE	IF	CITATIONS
1	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014, 63, 7-42.	6.1	1,116
2	Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. <i>Lancet</i> , The, 2018, 392, 400-408.	6.3	199
3	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012, 44, 1131-1136.	9.4	162
4	Gastric Antral Vascular Ectasia (GAVE): An Update on Clinical Presentation, Pathophysiology and Treatment. <i>Digestion</i> , 2008, 77, 131-137.	1.2	136
5	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.2	116
6	UK guidelines on oesophageal dilatation in clinical practice. <i>Gut</i> , 2018, 67, 1000-1023.	6.1	96
7	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	0.6	67
8	Identification of a primitive intestinal transcription factor network shared between esophageal adenocarcinoma and its precancerous precursor state. <i>Genome Research</i> , 2019, 29, 723-736.	2.4	50
9	Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. <i>PLoS Genetics</i> , 2017, 13, e1006879.	1.5	41
10	The current use of ultrasound to measure skeletal muscle and its ability to predict clinical outcomes: a systematic review. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 2298-2309.	2.9	33
11	Comparing outcome of radiofrequency ablation in Barrett's esophagus with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. <i>Endoscopy</i> , 2015, 47, 980-987.	1.0	32
12	Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma. <i>Molecular Cancer</i> , 2015, 14, 69.	7.9	30
13	Structured gastroenterological intervention and improved outcome for patients with chronic gastrointestinal symptoms following pelvic radiotherapy. <i>Supportive Care in Cancer</i> , 2013, 21, 2255-2265.	1.0	22
14	Risk factors for neoplastic progression in Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2011, 17, 3672.	1.4	22
15	Overview of bariatric surgery for the physician. <i>Clinical Medicine</i> , 2012, 12, 435-440.	0.8	21
16	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , 2016, 6, 32417.	1.6	20
17	Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 57-65.	3.7	18
18	The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus. <i>Journal of Clinical Pathology</i> , 2018, 71, 201-206.	1.0	17

#	ARTICLE	IF	CITATIONS
19	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , 2019, 145, 3389-3401.	2.3	17
20	Tele-Monitoring of Cancer Patients' Rhythms during Daily Life Identifies Actionable Determinants of Circadian and Sleep Disruption. <i>Cancers</i> , 2020, 12, 1938.	1.7	17
21	Glasgow Blatchford Score and risk stratifications in acute upper gastrointestinal bleed: can we extend this to 2 for urgent outpatient management?. <i>Clinical Medicine</i> , 2018, 18, 118-122.	0.8	16
22	Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?. <i>World Journal of Gastroenterology</i> , 2011, 17, 2781-90.	1.4	16
23	Research priority setting in Barrett's oesophagus and gastro-oesophageal reflux disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 824-831.	3.7	15
24	The yield of colonoscopy in average-risk patients with non-specific colonic symptoms. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1073-1077.	0.8	14
25	Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma. <i>ELife</i> , 2020, 9, .	2.8	14
26	Barrett's oesophagus: A qualitative study of patient burden, care delivery experience and follow-up needs. <i>Health Expectations</i> , 2019, 22, 21-33.	1.1	13
27	Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment. <i>World Journal of Gastroenterology</i> , 2011, 17, 2063.	1.4	11
28	FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. <i>BMC Research Notes</i> , 2015, 8, 676.	0.6	10
29	Dedicated service improves the accuracy of Barrett's oesophagus surveillance: a prospective comparative cohort study. <i>Frontline Gastroenterology</i> , 2019, 10, 128-134.	0.9	8
30	Gastric endoscopic submucosal dissection as a treatment for early neoplasia and for accurate staging of early cancers in a United Kingdom Caucasian population. <i>World Journal of Gastrointestinal Endoscopy</i> , 2017, 9, 561-570.	0.4	8
31	Comparative quantitative survey of patient experience in Barrett's oesophagus and other gastrointestinal disorders. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000357.	1.1	7
32	Learning curves and the influence of procedural volume for the treatment of dysplastic Barrett's oesophagus. <i>Gastrointestinal Endoscopy</i> , 2020, 92, 543-550.e1.	0.5	7
33	Biomarkers of normal tissue toxicity after pelvic radiotherapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 33-40.	0.5	3
34	283 Patients Undergoing Radiofrequency Ablation (RFA) for Barrett's Related Neoplasia Have Improved Outcomes With Decreasing Length's of Baseline Barrett's Eosophagus (BE) and Increasing Number of RFA Sessions. <i>Gastrointestinal Endoscopy</i> , 2013, 77, AB138.	0.5	3
35	Long-term follow-up of endoscopic submucosal dissection of gastric dysplasia and early neoplasia in a United Kingdom Caucasian population - a tertiary centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 18-26.	0.6	3
36	Patients' views on their experience of the delivery of single-sex accommodation within the endoscopy department: is it worth it?. <i>Frontline Gastroenterology</i> , 2017, 8, 13-18.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Accuracy of the revised Vienna Classification for predicting postendoscopic resection outcomes for gastric and oesophageal neoplasms: a retrospective cohort study of patients from a UK tertiary referral centre. <i>Journal of Clinical Pathology</i> , 2020, 73, 493-501.	1.0	2
38	Developing patient-orientated Barrett's oesophagus services: the role of dedicated services. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000829.	1.1	2
39	Endoscopic resection of early squamous neoplasia of the oesophagus: long-term follow-up in a UK population from a tertiary hospital. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 789-796.	0.8	1
40	Methylation panel as a diagnostic biomarker in Barrett's oesophagus: a comprehensive biomarker panel in a population-based screening programme?. <i>Journal of Laboratory and Precision Medicine</i> , 2018, 3, 37-37.	1.1	0